Tags

Type your tag names separated by a space and hit enter

Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections.
Expert Rev Anti Infect Ther. 2003 Jun; 1(1):21-43.ER

Abstract

The acyclic nucleoside phosphonates [HPMPC: cidofovir, Vistide; PMEA: adefovir dipivoxil, Hepsera; and PMPA: tenofovir, Viread] have proven to be effective in vitro (cell culture systems) and in vivo (animal models and clinical studies) against a wide variety of DNA virus and retrovirus infections, for example, cidofovir against herpesvirus [herpes simplex virus type 1 and 2, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus type 6, 7 and 8), polyoma-, papilloma-, adeno- and poxvirus (variola virus, cowpox virus, vaccinia virus, molluscum contagiosum virus and orf) infections; adefovir against herpesvirus, hepadnavirus [human hepatitis B virus] and retrovirus [HIV type-1 and 2, simian immunodeficiency virus and feline immunodeficiency virus] infections; and tenofovir against both hepadna- and retrovirus infections. Cidofovir has been officially approved for the treatment of cytomegalovirus retinitis in AIDS patients, tenofovir disoproxil fumarate (Viread) for the treatment of HIV infections (i.e., AIDS) and adefovir dipivoxil for the treatment of chronic hepatitis B.

Authors+Show Affiliations

Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgium. erik.declerq@rega.kuleuven.ac.be

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15482100

Citation

De Clercq, Eric. "Potential of Acyclic Nucleoside Phosphonates in the Treatment of DNA Virus and Retrovirus Infections." Expert Review of Anti-infective Therapy, vol. 1, no. 1, 2003, pp. 21-43.
De Clercq E. Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections. Expert Rev Anti Infect Ther. 2003;1(1):21-43.
De Clercq, E. (2003). Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections. Expert Review of Anti-infective Therapy, 1(1), 21-43.
De Clercq E. Potential of Acyclic Nucleoside Phosphonates in the Treatment of DNA Virus and Retrovirus Infections. Expert Rev Anti Infect Ther. 2003;1(1):21-43. PubMed PMID: 15482100.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections. A1 - De Clercq,Eric, PY - 2004/10/16/pubmed PY - 2004/10/29/medline PY - 2004/10/16/entrez SP - 21 EP - 43 JF - Expert review of anti-infective therapy JO - Expert Rev Anti Infect Ther VL - 1 IS - 1 N2 - The acyclic nucleoside phosphonates [HPMPC: cidofovir, Vistide; PMEA: adefovir dipivoxil, Hepsera; and PMPA: tenofovir, Viread] have proven to be effective in vitro (cell culture systems) and in vivo (animal models and clinical studies) against a wide variety of DNA virus and retrovirus infections, for example, cidofovir against herpesvirus [herpes simplex virus type 1 and 2, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus type 6, 7 and 8), polyoma-, papilloma-, adeno- and poxvirus (variola virus, cowpox virus, vaccinia virus, molluscum contagiosum virus and orf) infections; adefovir against herpesvirus, hepadnavirus [human hepatitis B virus] and retrovirus [HIV type-1 and 2, simian immunodeficiency virus and feline immunodeficiency virus] infections; and tenofovir against both hepadna- and retrovirus infections. Cidofovir has been officially approved for the treatment of cytomegalovirus retinitis in AIDS patients, tenofovir disoproxil fumarate (Viread) for the treatment of HIV infections (i.e., AIDS) and adefovir dipivoxil for the treatment of chronic hepatitis B. SN - 1478-7210 UR - https://www.unboundmedicine.com/medline/citation/15482100/Potential_of_acyclic_nucleoside_phosphonates_in_the_treatment_of_DNA_virus_and_retrovirus_infections_ L2 - http://www.tandfonline.com/doi/full/10.1586/14787210.1.1.21 DB - PRIME DP - Unbound Medicine ER -